Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01786135 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1 study of Burkitt Lymphoma and Lymphoma, Large B-Cell, Diffuse, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 6
- Study locations
NCT01786135 is a Phase 1 study of Burkitt Lymphoma and Lymphoma, Large B-Cell, Diffuse that has completed, run by Seagen. The registered enrollment target is 64 participants, below the 74-participant average among 22 other Burkitt Lymphoma trials with a reported enrollment target (14% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT01786135, a Phase 1 study of Burkitt Lymphoma and Lymphoma, Large B-Cell, Diffuse, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
Conditions Studied
Interventions
- DRUG SGN-CD19A
Study Locations (6)
California
- City of Hope National Medical Center - Duarte
- Stanford Cancer Center - Stanford
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center / University of Texas - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-02 |
| Est. Completion | 2017-02-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01786135
The ClinicalTrials.gov registry entry for NCT01786135 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 74-participant average among 22 other Burkitt Lymphoma trials with a reported enrollment target (14% lower). The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Burkitt Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which SGN-CD19A is the first listed.
NCT01786135 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT01786135 about?
NCT01786135 is a clinical study titled "A Safety Study of SGN-CD19A for B-Cell Lymphoma". This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
What is the current status of trial NCT01786135?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2013-02. Estimated completion is 2017-02-16.
What conditions does trial NCT01786135 study?
This clinical trial studies the following conditions: Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma.
What interventions are being tested in trial NCT01786135?
The interventions under investigation include: SGN-CD19A (DRUG).
Who is sponsoring clinical trial NCT01786135?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01786135 being conducted?
This trial has 6 study locations across Alabama, California, Florida, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burkitt Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
Study of SGR-1505 in Mature B-Cell Neoplasms
RECRUITING · Phase 1
-
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
RECRUITING · Phase 1
-
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.